# VISTA-16 Trial: Evaluation of Safety and Efficacy of Short-term A-002 Treatment in Subjects With Acute Coronary Syndrome

> **NCT01130246** · PHASE3 · TERMINATED · sponsor: **Anthera Pharmaceuticals** · enrollment: 5189 (actual)

## Conditions studied

- Acute Coronary Syndrome

## Interventions

- **DRUG:** A-002, varespladib methyl
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01130246
- **Lead sponsor:** Anthera Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-05
- **Primary completion:** 2012-03
- **Final completion:** 2012-03
- **Target enrollment:** 5189 (ACTUAL)
- **Why stopped:** Lack of efficacy
- **Last updated:** 2012-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01130246

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01130246, "VISTA-16 Trial: Evaluation of Safety and Efficacy of Short-term A-002 Treatment in Subjects With Acute Coronary Syndrome". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01130246. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*